PRAME Shows Promise as a Treatment Avenue in Melanoma, Other Solid Tumors
Source: OncLive, February 2024
Preferentially expressed antigen in melanoma has emerged as a target for treatment development in multiple solid tumors.
As investigators continue to refine and carve out a role for targeted therapies in the treatment paradigm across tumor types, preferentially expressed antigen in melanoma (PRAME) has emerged as an intriguing treatment target in multiple solid tumors.
PRAME encodes the HLA-A24 antigen and is a member of the cancer testis antigen family of genes that can act as an oncogene or a tumor suppressor gene in multiple cancer types; high expression of PRAME is observed in 88% of primary and 95% of metastatic melanoma tissues. PRAME expression is regulated by SOX17, MZF1, miR-211, and miR-421, and overexpression affects several cellular processes via downstream regulation of targets such as p21, p53, RAR, TRAIL, S100A4, and HSP27.